Methyl aminolevulinate hydrochloride
Based on 1 publication(s) in Google Scholar
Methyl aminolevulinate hydrochloride is a sensitizer used in photodynamic therapy (PDT). Methyl aminolevulinate hydrochloride penetrates the skin and induces the production of photoactive porphyrins including protoporphyrin IX in cells; upon exposure to appropriate light, it generates ROS, which triggers cellular oxidation and cell death. Methyl aminolevulinate hydrochloride acts as a photo-damage reversing agent through epidermal reconstruction, cytokine-mediated activation of dermal fibroblasts, elastin breakdown, new collagen formation, and compression of dilated capillaries. Methyl aminolevulinate hydrochloride reduces the expression of the proliferation marker Ki-67 and the early skin carcinogenesis marker TP53. Methyl aminolevulinate hydrochloride delays the onset of ultraviolet-induced skin tumors and reduces tumor burden in hairless mice. Methyl aminolevulinate hydrochloride is applicable to research related to actinic keratosis and basal cell carcinoma.
For research use only. We do not sell to patients.
- Purity: 98.98%
- CAS No.: 79416-27-6
- Formula: C6H12ClNO3
- Molecular Weight:181.62
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Methyl aminolevulinate hydrochloride
More
Biological Activity
Methyl aminolevulinate (0.0001-1.4 mmol/L) hydrochloride induces concentration-dependent formation of photoactive porphyrins in cultures of mouse adenocarcinoma LM2 cells, with the highest yield of 48 ng/105 cells observed at the concentration of 1.4 mmol/L; additionally, 90% of porphyrins remain intracellular at all tested concentrations[1].
Methyl aminolevulinate (1.2-1.8 mmol/L, 3 h) hydrochloride shows no intrinsic cytotoxicity against mouse adenocarcinoma LM2 cells at the concentration of 1.8 mmol/L, but induces 98% cell death when cells are treated with 1.2 mmol/L for 3 h followed by irradiation with 3 J/cm2[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:murine adenocarcinoma LM2 cell
-
Concentration:1.8 mmol/L (intrinsic cytotoxicity); 1.2 mmol/L (photodynamic cytotoxicity)
-
Incubation Time:3 h (photodynamic cytotoxicity)
-
Result:Showed no cytotoxicity to LM2 cells at 1.8 mmol/L when used alone.
Induced 98% cell death when used at 1.2 mmol/L for 3 h followed by irradiation with 3 J/cm2 light.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hairless mice (UV radiation-induced tumor model)[1]
-
Dosage:8-20%
-
Administration:topical; weekly; 26 weeks (UV-exposed mice); up to 36 weeks (non-UV-exposed mice)
-
Result:Delayed the appearance of UV-induced small tumors (AK or in situ SCC) by 2-3 weeks.
Delayed larger lesions (invasive SCC) by 5-7 weeks.
Caused an approximate 2- to 2.5-fold decrease in the number of UV-induced tumors per mouse after 26 weeks.
Significantly increased the tumor-free time on the methyl aminolevulinate-PDT side compared with the vehicle-PDT side in contralaterally treated mice.
Prevented tumor formation in non-UV-exposed mice treated for up to 36 weeks.
Induced higher levels of photoactive porphyrins (PAPs) in UV-induced tumors compared with normal skin of hairless mice.
Induced PAP formation only at the sites where it was applied.
Caused faster clearance of PAP than that formed by topical aminolevulinic acid.
Chemical Information
-
CAS No. 79416-27-6
-
Appearance Solid
-
Molecular Weight 181.62
-
Formula C6H12ClNO3
-
Color White to off-white
-
SMILES
O=C(OC)CCC(CN)=O.[H]Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Sci Data
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]2024 Sep 19;11(1):1024. PMID: 39300112
Solvent & Solubility
H2O : 100 mg/mL (550.60 mM; Need ultrasonic)
DMSO : 100 mg/mL (550.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (13.77 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (13.77 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Siddiqui MA, et al. Topical methyl aminolevulinate. Am J Clin Dermatol. 2004;5(2):127-37; discussion 138-40. [Content Brief]
[2]. Szeimies RM, et al. Photoaging and Cosmetic Result with Artificial Daylight Photo-dynamic Therapy Using Methyl Aminolevulinate. Acta Derm Venereol. 2025;105:adv43245. Published 2025 Apr 22. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 5.5060 mL | 27.5300 mL | 55.0600 mL | 137.6500 mL |
| 5 mM | 1.1012 mL | 5.5060 mL | 11.0120 mL | 27.5300 mL | |
| 10 mM | 0.5506 mL | 2.7530 mL | 5.5060 mL | 13.7650 mL | |
| 15 mM | 0.3671 mL | 1.8353 mL | 3.6707 mL | 9.1767 mL | |
| 20 mM | 0.2753 mL | 1.3765 mL | 2.7530 mL | 6.8825 mL | |
| 25 mM | 0.2202 mL | 1.1012 mL | 2.2024 mL | 5.5060 mL | |
| 30 mM | 0.1835 mL | 0.9177 mL | 1.8353 mL | 4.5883 mL | |
| 40 mM | 0.1377 mL | 0.6883 mL | 1.3765 mL | 3.4413 mL | |
| 50 mM | 0.1101 mL | 0.5506 mL | 1.1012 mL | 2.7530 mL | |
| 60 mM | 0.0918 mL | 0.4588 mL | 0.9177 mL | 2.2942 mL | |
| 80 mM | 0.0688 mL | 0.3441 mL | 0.6883 mL | 1.7206 mL | |
| 100 mM | 0.0551 mL | 0.2753 mL | 0.5506 mL | 1.3765 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Methyl aminolevulinate hydrochloride Related Classifications
HY-A0169A Related Classifications
Powered by Bioz